Mark Douglas

Professor Mark Douglas is a Professor of Infectious Diseases and Hepatic Medicine at the University of Sydney's Westmead Clinical School, within the Faculty of Medicine and Health. He leads the Viral Hepatitis Pathogenesis group at the Storr Liver Centre and is affiliated with the Westmead Institute for Medical Research. His research focuses on hepatitis viruses (HBV, HCV, HDV), lipid metabolism, and antiviral resistance. He runs liver clinics for hepatitis patients and treats HIV and other infections at Westmead Hospital.

Education and professional background: Dr. Douglas completed postdoctoral training at the MRC Virology Unit in Glasgow (2005-2007) and holds a Fellow of the Royal Australasian College of Physicians. He has authored over 100 peer-reviewed publications, including a book on herpes simplex virus transport.

Research interests include viral hepatitis pathogenesis, host-virus interactions, and developing personalized therapies. Current projects target HBV cure strategies, HCV resistance surveillance, and improving treatment access for disadvantaged groups.

Recent articles highlight advancements in HBV immune response modulation, CAC-driven liver inflammation, and TM6SF2 inhibition for viral secretion suppression. His work bridges basic science and clinical translation, addressing global health challenges in viral hepatitis.

• Awards: NHMRC CJ Martin Fellowship (2005)
• Grants: Includes studies on HBV cccDNA diagnostics, HCV resistance surveillance, and TM6SF2 inhibition.

As a Research Academic Director in Clinical Sciences, Dr. Douglas supervises postgraduate students like Harout AJOYAN and Delgerbat BOLDBAATAR. Collaborations span institutions in Indonesia (Eijkman Institute, Hasanuddin University) and the UK (University of Glasgow, Wellcome Trust Sanger Institute).